

Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement

Information for the public

Published: 25 August 2021

www.nice.org.uk

Pemigatinib (Pemaryze) is available on the NHS. It is a possible treatment for locally advanced or metastatic bile duct cancer (cholangiocarcinoma) in adults, if their disease:

- has an abnormal form of a protein called fibroblast growth factor receptor 2 (FGFR2),
and
- has progressed after systemic therapy, such as chemotherapy.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [AMMF - The Cholangiocarcinoma Charity](#)
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4246-6